199 related articles for article (PubMed ID: 10969268)
1. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome.
Zacharin M; O'Sullivan M
J Pediatr; 2000 Sep; 137(3):403-9. PubMed ID: 10969268
[TBL] [Abstract][Full Text] [Related]
2. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
Matarazzo P; Lala R; Masi G; Andreo M; Altare F; de Sanctis C
J Pediatr Endocrinol Metab; 2002; 15 Suppl 3():929-37. PubMed ID: 12199352
[TBL] [Abstract][Full Text] [Related]
3. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome.
Lala R; Matarazzo P; Bertelloni S; Buzi F; Rigon F; de Sanctis C
Acta Paediatr; 2000 Feb; 89(2):188-93. PubMed ID: 10709889
[TBL] [Abstract][Full Text] [Related]
4. Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia.
Isaia GC; Lala R; Defilippi C; Matarazzo P; Andreo M; Roggia C; Priolo G; de Sanctis C
Calcif Tissue Int; 2002 Aug; 71(2):121-8. PubMed ID: 12200645
[TBL] [Abstract][Full Text] [Related]
5. [Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome].
Pfeilschifter J; Ziegler R
Med Klin (Munich); 1998 Jun; 93(6):352-9. PubMed ID: 9662942
[TBL] [Abstract][Full Text] [Related]
6. Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood.
Chan B; Zacharin M
J Pediatr Endocrinol Metab; 2006 Jan; 19(1):75-80. PubMed ID: 16509531
[TBL] [Abstract][Full Text] [Related]
7. Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome.
Leet AI; Chebli C; Kushner H; Chen CC; Kelly MH; Brillante BA; Robey PG; Bianco P; Wientroub S; Collins MT
J Bone Miner Res; 2004 Apr; 19(4):571-7. PubMed ID: 15005844
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome.
Lala R; Matarazzo P; Andreo M; Marzari D; Bellone J; Corrias A; de Sanctis C;
J Pediatr Endocrinol Metab; 2006 May; 19 Suppl 2():583-93. PubMed ID: 16789621
[TBL] [Abstract][Full Text] [Related]
9. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
10. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.
Chapurlat RD; Hugueny P; Delmas PD; Meunier PJ
Bone; 2004 Jul; 35(1):235-42. PubMed ID: 15207763
[TBL] [Abstract][Full Text] [Related]
11. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
[TBL] [Abstract][Full Text] [Related]
12. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
[TBL] [Abstract][Full Text] [Related]
13. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone.
Plotkin H; Rauch F; Zeitlin L; Munns C; Travers R; Glorieux FH
J Clin Endocrinol Metab; 2003 Oct; 88(10):4569-75. PubMed ID: 14557424
[TBL] [Abstract][Full Text] [Related]
14. Pamidronate for fibrous dysplasia due to McCune Albright Syndrome.
Kochar IP; Kulkarni KP
Indian Pediatr; 2010 Jul; 47(7):633-5. PubMed ID: 20683120
[No Abstract] [Full Text] [Related]
15. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
Chapurlat RD; Delmas PD; Liens D; Meunier PJ
J Bone Miner Res; 1997 Oct; 12(10):1746-52. PubMed ID: 9333137
[TBL] [Abstract][Full Text] [Related]
16. EFFICACY AND SAFETY OF BISPHOSPHONATE THERAPY IN MCCUNE-ALBRIGHT SYNDROME-RELATED POLYOSTOTIC FIBROUS DYSPLASIA: A SINGLE-CENTER EXPERIENCE.
Wang Y; Wang O; Jiang Y; Li M; Xia W; Meng X; Xing X
Endocr Pract; 2019 Jan; 25(1):23-30. PubMed ID: 30383490
[TBL] [Abstract][Full Text] [Related]
17. Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases.
Chan B; Zacharin M
J Clin Endocrinol Metab; 2006 Jun; 91(6):2017-20. PubMed ID: 16551739
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate therapy for fibrous dysplasia.
DiMeglio LA
Pediatr Endocrinol Rev; 2007 Aug; 4 Suppl 4():440-5. PubMed ID: 17982393
[TBL] [Abstract][Full Text] [Related]
19. Fibrous dysplasia of bone and McCune-Albright syndrome.
Chapurlat RD; Orcel P
Best Pract Res Clin Rheumatol; 2008 Mar; 22(1):55-69. PubMed ID: 18328981
[TBL] [Abstract][Full Text] [Related]
20. Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia.
Majoor BC; Appelman-Dijkstra NM; Fiocco M; van de Sande MA; Dijkstra PS; Hamdy NA
J Bone Miner Res; 2017 Feb; 32(2):264-276. PubMed ID: 27649526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]